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assumptions are explored. Further assurances of internal validity
include the replication of the model in another software. CON-
CLUSION: Approaches to model validation should be included
as part of any publication. Budgetary and time allocation should
take model validation into account given the increased impor-
tance placed on the outcomes of health economic models.
PMC34
BIBLIOGRAPHIC REVIEW OF DISCRETE EVENTS SIMULATION
STUDIES IN HEALTHTECHNOLOGY EVALUATION
Monleon T1, Rodriguez-Barrios JM2, Serrano D2
1University of Barcelona, Barcelona, Spain, 2Medtronic Ibérica SA,
Madrid, Spain
OBJECTIVES: The use of computational models to assess thera-
peutic alternatives has been growing in importance in the eco-
nomic evaluation of health technologies and services during the
last years, becoming a more relevant and helpful tool for decision
making in health care. Until now, two types of models have been
used: decision trees and Markov chains, nevertheless, they both
show important limitations when addressing complex processes
or pathologies, and that’s why interest in, and use of discrete
event simulation(DES) is growing, specially in economic evalua-
tion and medical decision making related journals. The objective
of this study was to perform a bibliographic review of DES
studies, and to evaluate their advantages ad limitations where
compared with other broadly used decision analytic model tech-
niques. METHODS: A structured bibliographic search using
Medline, principally, was performed to search in the scientiﬁc
literature the keywords: Health technology, computer simula-
tion, economic evaluation models and discrete event simulation.
A system of selection of the search based on authors peer reviews
and expert criteria was established. RESULTS: Forty-two papers
were selected using DES alone or combined with Markov chains
and decision trees. The result reﬂects the increasing number of
the DES in after 1998, specially in the last 5 years. A classiﬁca-
tion of the selected articles was performed. These classiﬁcation
revealed the use of secondary data in these model development.
Studies come in a highest percentage from UK, USA, and
Holland, the temporal perspective was from less than 1 up to 50
years; sensitivity analysis was performed in the mentioned studies
and Simul8, Arena, MS Excel were the most frequent used soft-
wares. CONCLUSION: The results reﬂect that the use and
acceptance of DES is growing internationally in health technol-
ogy and health care analysis, so it would be an useful tool to
simulate some complicated system and processes.
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OBJECTIVES: To analyze a health resources utilization claim
database in order to derive direct health costs of treating patients
with Fibromyalgia under routine medical practice at PCS.
METHODS: A 12-month retrospective study was performed
using computerized medical records from a health provider data-
base; BSA. Analysis was conducted from a 3r-payer perspective
during the year 2006. Health resources utilization included both
those of the primary care (PC) level (drugs, complementary tests,
medical visits, etc.) and those of the specialized care (SC) as well.
SC included emergency visits, hospitalizations, and tests and
drugs prescribed by specialist. Men and women above 18-years
included in the data base (n = 63,526) were analyzed. Fibromy-
algia was diagnosed according with CIE-10 criteria. Descriptive
statistics and ANCOVA models were used. RESULTS: One-
thousand-eighty-one subjects [96.7% women, 54.2 (10.1) years]
fulﬁlled CIE-10 criteria for Fibromyalgia amongst the 63,526
database subjects: 1.7%. Charlson index was no different in
Fibromyalgia patients vs controls (the rest of sample analyzed),
p = 0.212. After adjusting by age and sex, yearly total health
costs per patient were €614 higher (+66%) on average in Fibro-
myalgia than in controls; €1,550 (95% CI: 1,341–1,760) vs.
€937 (927–945), p < 0.0001. Both PC and SC annual costs were
signiﬁcantly higher in Fibro patients; mean per patient adjusted
difference of €395 (276–513, p < 0.0001) and €219 (74–364,
p = 0.003), respectively. Total annual drug costs were consider-
ably higher in patients with Fibromyalgia; €591 (485–696) vs.
€361 (356–366), p < 0.0001. Age correlated moderate but sig-
niﬁcantly with yearly PC, drug and total per patient health costs;
r = 0.324, 0.325, and 0.278, respectively, p < 0.001 in all cases.
CONCLUSION: Compared with controls, subjects with Fibro-
myalgia were associated to higher annual total direct health costs
in the primary care setting. Drugs represented a considerable
portion of health resources costs devoted to these patients. Age,
but not sex, was associated with higher costs.
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OBJECTIVES: To analyze the impact of PRO measurements on
longitudinal direct health costs when treating Fibromyalgia
under routine medical practice at PCS. METHODS: Retrospec-
tive sub-analysis of subjects above 18-years, with Fibromyalgia
according to CIE-10, included in a claim database (BSA), who
received the point-administration of FIQ, EQ-5D and BPI ques-
tionnaires after 12-months of health resources utilization record
and deriving total health direct costs. Resources included emer-
gency visits, hospitalizations, complementary tests, drugs and
medical visits occurred both at primary (PC) and specialized care
(SC) level. RESULTS: One-thousand-eighty-one subjects [96.7%
women, 54.2 (10.1) years] fulﬁlled CIE-10 criteria for Fibromy-
algia amongst 63,526 subjects in the database. PRO question-
naires were administered to a random sample of 200 patients
[97.5% women, 53.0 (8.5) years] showing no statistically differ-
ences in health resources utilization and costs vs. the other Fibro-
myalgia patients. Patient disease impact was severe [total FIQ;
71.7 (16.9)] showing weak but signiﬁcant correlation with total
annual health costs; r = 0.202 (p = 0.004). Work/domestic-
interference BPI-item correlated signiﬁcantly, but also weak, with
PC, drugs and total health costs; r = 0.216, 0.218, 0.242, respec-
tively (p < 0.01 in all cases). BPI sleep interference correlated
slightly but signiﬁcant with total costs; r = 0.203 (p = 0.004).
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Severity of pain (BPI-item-3) was statistically associated with
total annual health costs; €1255 (932), €1473 (1198) and
€1950 (1391) for mild, moderate and severe pain respectively,
p = 0.017. Walking (FIQ1g) and work/domestic (BPI5d) inter-
ference were positive predictors for per patient annual drug
costs, while pain problems and 12-month health state change
(EQ-5D items 4 and 6) were negative predictors (R2 = 0.283,
p < 0.001). CONCLUSION: In the primary care setting, annual
per patient total direct health cost of Fibromyalgia showed
weak but statistically signiﬁcant association with patient disease
interference and severity of pain. Less drug costs could be asso-
ciated with poorer outcomes in term of health state change and
level of pain.
OBESITY—Clinical Outcomes Studies
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OBJECTIVES: To describe the association between obesity and
costs and use of antipsychotic drugs (APDs) in patients seen by
seven Spanish primary care teams (PCTs), under usual medical
practice. METHODS: A retrospective, multicenter study was
made with patients receiving APD treatment during year 2005.
Obesity was considered according to W.H.O. as a body mass
index (BMI) > 30 kg/m2. Main measurements included APD
consumption, sociodemographics, comorbidity/episodes, Charl-
son index (severity), and costs (semi-ﬁxed and variable, visits,
diagnostic/therapeutic procedures, referrals and drugs). Descrip-
tive statistics, logistic regression model and analysis of covari-
ance (ANCOVA) with Bonferroni correction were applied.
RESULTS: A total of 42,437 patients (age: 50.9  17.8 years,
women: 59.9%) were included in the analysis. Obesity was
present in 27.3% [CI: 26.9–27.7%]), with a 1.3% receiving
APDs (typical: 48.8%, atypical: 51.2%; p = NS). Patients with
obesity showed higher annual average of episodes (7.0  4.0
vs. 5.5  3.6), visits (12.1  9.8 vs. 9.1  8.5) and severity
(0.5  0.7 vs. 0.3  0.6), p < 0.001. In the logistic regression
analysis, obesity was related to APD use (OR = 1.5; CI: 1.3–
1.8), hypertension (OR = 2.4; CI: 2.2 2.5), diabetes (OR = 1.4;
CI: 1.3–1.5) and dyslipidemia (OR = 1.3; CI: 1.2–1.4),
p < 0.001 in all cases. After adjusting, BMI was slightly higher
in subjects on APD; 27.8 kg/m2 vs. 27.4 kg/m2, p = 0.002.
Mean crude and adjusted (age, gender and comorbidities)
annual costs were signiﬁcantly higher in obese patients than
in non obese; €980.89  1,467.49 vs. €637.64  1,244.49,
p < 0.001, and €810.88 vs. €693.79, p < 0.001 respectively. All
components of per patient per year costs were higher in the
group of obese patients, p < 0.0001. CONCLUSION: Obesity
was associated with the use of APDs and the presence of hyper-
tension, diabetes and dyslipidemia. No differences were found
between using typical or atypical APDs. Obese patients pre-
sented more comorbidity, use of health resources and associated
costs.
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OBJECTIVES: Clinical trials have demonstrated that rimona-
bant leads to signiﬁcant improvements in cardiometabolic risk
factors, including weight, waist circumference, lipids, and fasting
glucose. This study translates these beneﬁts into expected out-
comes when rimonabant is administered to adults with dyslipi-
demia and a BMI>27 kg/m2 in addition to diet and exercise.
METHODS: A discrete event simulation was developed to
project outcomes in individuals at increased cardiometabolic
risk. Data from the Health Survey of England are used to create
simulated adults free of cardiovascular disease (CVD) and dia-
betes but who are overweight or obese and have either elevated
triglycerides or low HDL. Equations derived from the RIO trials
are used to calculate changes in individual cardiometabolic risk
factors as a function of time, treatment and baseline risk factors.
Treatments considered are diet and exercise alone or with the
addition of rimonabant 20mg. The simulation determines when
individuals develop CVD, diabetes, or microvascular disease
(MVD) using published equations from Framingham, UKPDS
and the San Antonio Heart Study. RESULTS: After one year,
simulated patients on rimonabant lose an average of 4.4 kg com-
pared to only 0.4 kg with diet and exercise alone. On average
HDL levels increase by 0.07 mmol/L more with rimonabant;
triglyceride levels fall by 0.27 mmol/L more. Over their lifetimes,
1000 rimonabant users experience 9 fewer CVD events, live 66
years longer, and avoid 334 years with diabetes. MVD events fall
by 30. Extending treatment to 10 years results in 11% fewer
CVD events and life expectancy gains of 234 years compared to
one year of treatment. CONCLUSION: These results suggest
that in overweight or obese patients with dyslipidemia, cardi-
ometabolic risk factor improvements associated with rimona-
bant, which extend beyond those expected with diet and exercise
alone, could translate to concrete health gains by preventing or
delaying diabetes, MVD and acute CVD.
OBESITY—Methods and Concepts
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OBJECTIVES: The WinBUGS software is a powerful tool to
analyze data in the framework of the bayesian theory and has
recently been shown useful in developing complex probabilistic
Markov models. Despite some clear advantages, this technique
has not been fully exploited in health economic evaluations. We
developed a cost-utility and budget impact analysis of the use of
orlistat in Italian obese patients through this innovative model-
ling approach. METHODS: A probabilistic Markov model has
been developed to simulate outcomes of the obese Italian popu-
lation after four years of orlistat treatment plus six years of
follow-up. The efﬁcacy of the treatment derives from the
XENDOS study. The model integrates a Framingham Heart
Study-based algorithm to estimate cardiovascular risk. The
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